iShares US Pharmaceuticals ETF
IHE
IHE
113 hedge funds and large institutions have $118M invested in iShares US Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
18% less capital invested
Capital invested by funds: $143M → $118M (-$25.2M)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Holders
113
Holding in Top 10
–
Calls
$441K
Puts
$206K
Top Buyers
| 1 | +$3.81M | |
| 2 | +$3.04M | |
| 3 | +$2.89M | |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$2.28M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.25M |
Top Sellers
| 1 | -$6.35M | |
| 2 | -$5.05M | |
| 3 | -$3.6M | |
| 4 |
AWS
Atria Wealth Solutions
New York
|
-$2.95M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.02M |